Predictive Oncology (NASDAQ: POAI) recently entered an
agreement with POAI CEO Dr. Carl Schwartz to exchange a $2.1 million promissory
note for newly issued equity (http://ibn.fm/lzYPh).
An article discussing the company reads, “‘This agreement enables the company
to strengthen its balance sheet and simplify its capital structure at a
critical juncture in our quest to commercialize our highly valuable database of
cancer tumors for the advancement of predictive medicine,’ Schwartz said in a
news release. ‘At the same time, it reinforces my commitment and demonstrates
my belief in our ability to emerge as a leader in the application of artificial
intelligence to oncology therapies.’ . . . According to the agreement, Schwartz
will exchange the promissory note for shares of common stock, $0.01 par value
of Predictive Oncology at market value. In addition, Schwartz agrees not to
sell or otherwise transfer one-half of the shares for three months after the
date of the exchange agreement and not to sell or otherwise transfer the
remaining shares for six months after the date of the agreement. Negotiated
between POAI and Schwartz on an arms-length basis, the agreement was approved
by the Audit Committee of the company’s board of directors in accordance with
Nasdaq listing requirements.”
To view the full article, visit http://ibn.fm/ZfB9k
About Predictive Oncology Inc.
Predictive Oncology operates through three segments
(domestic, international and other) that contain four subsidiaries; Helomics,
TumorGenesis, Skyline Medical and Skyline Europe. Helomics applies artificial
intelligence to its rich data gathered from patient tumors to both personalize
cancer therapies for patients and drive the development of new targeted
therapies in collaborations with pharmaceutical companies. Helomics’
CLIA-certified lab provides clinical testing that assists oncologists in
individualizing patient-treatment decisions by providing an evidence-based road
map for therapy. In addition to its proprietary precision oncology platform,
Helomics offers boutique CRO services that leverage its TruTumor(TM),
patient-derived tumor models coupled with a wide range of multi-omics assays
(genomics, proteomics and biochemical), and an AI-powered proprietary
bioinformatics platform to provide a tailored solution to its clients’ specific
needs. Predictive Oncology’s TumorGenesis subsidiary is developing a new rapid
approach to growing tumors in the laboratory, which essentially “fools” cancer
cells into thinking they are still growing inside a patient. Its proprietary
Oncology Discovery Technology Platform Kits will assist researchers and
clinicians to identify which cancer cells bind to specific biomarkers. Once the
biomarkers are identified, they can be used in TumorGenesis’ Oncology Capture
Technology Platforms, which isolate and help categorize an individual patient’s
heterogeneous tumor samples to enable the development of patient-specific
treatment options. Helomics and TumorGenesis are focused on ovarian cancer.
Predictive Oncology’s Skyline Medical division markets its patented and
FDA-cleared STREAMWAY System, which automates the collection, measurement and
disposal of waste fluid, including blood, irrigation fluid and others, within a
medical facility, through both domestic and international divisions. The
company has achieved sales in five of the seven continents through both direct
sales and distributor partners. For more information, visit the company’s
website at www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates
relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
